Cellectis Company Top Insiders

CMVLF Stock  USD 4.40  0.00  0.00%   
Cellectis employs about 294 people. The company is managed by 10 executives with a total tenure of roughly 63 years, averaging almost 6.0 years of service per executive, having 29.4 employees per reported executive. Examination of Cellectis' management performance can provide insight into the company performance.
Andre Choulika  Chairman
Chairman of the Board and CEO, Member of the Executive Committee
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Cellectis Management Team Effectiveness

The company has return on total asset (ROA) of (0.2408) % which means that it has lost $0.2408 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.557) %, meaning that it generated substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities.
Cellectis holds a total of 55.59 Million outstanding shares. Almost 90.2 percent of Cellectis outstanding shares are held by general public with 9.8 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Cellectis in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cellectis, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Cellectis Workforce Comparison

Cellectis SA is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 314. Cellectis totals roughly 294 in number of employees claiming about 94% of stocks in Biotechnology industry.

Cellectis SA Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Cellectis SA Price Series Summation is a cross summation of Cellectis price series and its benchmark/peer.

Cellectis Notable Stakeholders

A Cellectis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cellectis often face trade-offs trying to please all of them. Cellectis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cellectis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Andre ChoulikaChairman of the Board and CEO, Member of the Executive CommitteeProfile
David SourdiveCo-Founder, Executive VP of Corporate Devel. and DirectorProfile
MarieBleuenn TerrierGeneral Counsel, Member of the Executive CommitteeProfile
Dr MBAChief OfficerProfile
Valerie CrosPrincipal OfficerProfile
Kyung NamWortmanEx OfficerProfile
Philippe DuchateauChief Scientific OfficerProfile
Pascalyne WilsonDirector CommunicationsProfile
Jean EpinatChief OfficerProfile
MSc MScChief OfficerProfile
String symbol = request.getParameter("s");

About Cellectis Management Performance

The success or failure of an entity such as Cellectis SA often depends on how effective the management is. Cellectis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cellectis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cellectis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people.

Cellectis Workforce Analysis

Traditionally, organizations such as Cellectis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cellectis within its industry.

Cellectis Manpower Efficiency

Return on Cellectis Manpower

Revenue Per Employee194.9K
Revenue Per Executive5.7M
Net Loss Per Employee388.4K
Net Loss Per Executive11.4M
Working Capital Per Employee812.9K
Working Capital Per Executive23.9M

Complementary Tools for Cellectis Pink Sheet analysis

When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Valuation
Check real value of public entities based on technical and fundamental data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stocks Directory
Find actively traded stocks across global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.